Loading...
Dengue infection incidence continues to increase; nearly half the world's population lives in dengue-endemic areas. TAK-003 is a tetravalent vaccine candidate based on a live-attenuated dengue serotype-2 virus (DENV-2) which provides the genetic backbone for all four dengue serotypes. Investigators report results from a manufacturer-supported, double-blind, placebo-controlled phase 3 trial of TAK-003 in healthy children (4−16 years) at 26 dengue-endemic sites in the Americas and Asia. Participants (>20,000) were randomly assigned (2:1 ratio) to receive two doses of vaccine (0, 3 months) or saline placebo administered subcutaneously. Results are reported for 12 months after vaccination completion.
Efficacy against virologically confirmed deng…